Assessment Status | Rapid Review Complete |
HTA ID | 23064 |
Drug | Tebentafusp |
Brand | Kimmtrak® |
Indication | Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. |
Assessment Process | |
Rapid review commissioned | 10/10/2023 |
Rapid review completed | 13/11/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tebentafusp compared with the current standard of care. |